Callyope vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Callyope (Paris, AWS Pioneers 2026) raised .41M seed with 8 clinical trials ongoing, using speech AI to detect psychiatric deterioration early and deliver objective data between visits.
About
Callyope is a Paris-based clinical AI company founded to improve outcomes in mental health through passive, continuous monitoring. The company applies speech analysis and machine learning to detect early signals of psychiatric deterioration, enabling clinicians to intervene before crises occur. Its core technology processes vocal biomarkers to track mood, cognition, and behavioral patterns over time without requiring patients to self-report symptoms.\n\nCallyope's platform is designed for integration within clinical workflows, targeting psychiatrists, mental health hospitals, and digital health providers. The product supports remote patient monitoring between visits, generating objective data streams that augment clinician judgment. Unlike consumer wellness apps, Callyope operates within regulated clinical environments and is built to meet the evidentiary standards required for reimbursement and adoption in European and US health systems.\n\nThe company raised a $2.41 million seed round to fund product development and clinical validation. It currently has eight clinical trials ongoing and was selected for the AWS Healthcare Accelerator Pioneers 2026 cohort, reflecting recognition of its technical and scientific rigor. Callyope's pipeline of trial data positions it to pursue regulatory clearance and reimbursement pathways, which would unlock hospital procurement and enterprise mental health contracts at scale.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.